- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04359485
New Score for Pseudo- Acanthosis Nigricans
April 22, 2020 updated by: Rana F Hilal, MD, Kasr El Aini Hospital
Use Of A Novel Quantitative Tool For Evaluation of Pseudo- Acanthosis Nigricans: Acanthosis Nigricans Area And Severity Index
Each side of the neck pseudo acanthosis nigricans was randomized in to either receiving glycolic acid peel or saline.
Evaluation was done at baseline and after 3 sessions 2 weeks apart by percentage involvement and by ANASI score
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Kasr El Ainy university hospital, Faulty of medicine,Cairo university
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- mild to moderate severity
- age > 18 years old
Exclusion Criteria:
- Pregnant and lactating patients,
- patients with systemic diseases as connective tissue disease, diabetes,
- skin infection
- use of immunosuppressive drugs
- Susceptibility for post peel hazards as hyperpigmentation
- scarring and keloidal tendency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Saline
|
Sodium chloride
|
Experimental: glycolic acid peel
|
Glycolic acid peel 70% applied in 3 coats medium depth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage involvement
Time Frame: 6 months to 1 year
|
Degree of severity expressed as a percentage
|
6 months to 1 year
|
Acanthosis Nigricans Area and Severity Index score
Time Frame: 6 months to 1 year
|
New Score calculating severity and area as a number minimum value is 0 and maximum value is 40 the higher the number of the score the worse the affection
|
6 months to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2019
Primary Completion (Actual)
November 1, 2019
Study Completion (Anticipated)
June 1, 2020
Study Registration Dates
First Submitted
April 21, 2020
First Submitted That Met QC Criteria
April 22, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
April 24, 2020
Last Update Submitted That Met QC Criteria
April 22, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EgyANASI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pseudo Acanthosis Nigricans
-
Srinakharinwirot UniversityRecruitingHyperpigmentation | Acanthosis NigricansThailand
-
Cairo UniversityNot yet recruiting
-
Jinnah Postgraduate Medical CentreCompletedAcanthosis NigricansPakistan
-
Shanghai 10th People's HospitalCompletedObesity | Acanthosis NigricansChina
-
Juan Pablo Castanedo-CazaresHospital Central "Dr. Ignacio Morones Prieto"UnknownAcanthosis NigricansMexico
-
Henry Ford Health SystemCompletedHyperinsulinemia | Acanthosis Nigricans | Spectroscopic AnalysisUnited States
-
University of HawaiiUniversity of Alaska Fairbanks; University of Guam; Northern Marianas College; American...CompletedObesity | Acanthosis Nigricans | Central ObesityUnited States
-
National Center for Research Resources (NCRR)UnknownObesity | Diabetes | Glucose Intolerance | Acanthosis NigricansUnited States
-
Shen QuRecruitingInsulin Resistance | Morbid Obesity | Bariatric Surgery Candidate | Insulin Sensitivity | Acanthosis NigricansChina
-
University of GuadalajaraUniversidad de Granada; Tecnológico Nacional de México, campus Ciudad GuzmánActive, not recruitingHyperglycemia | Physical Activity | Body Composition | Blood Pressure | Hypercholesterolemia | Hypertriglyceridemia | Gut Microbiota | HDLC | Eating Behavior | Acanthosis Nigricans | Food Intake | Diet QualityMexico
Clinical Trials on Glycolic acids peel 70%
-
National University Hospital, SingaporeUnknown
-
National University Hospital, SingaporeUnknown
-
Boston Medical CenterWithdrawn
-
Assiut UniversityUnknown
-
Hanyang UniversityCompletedObesityKorea, Republic of
-
Galderma R&DCompleted
-
Combined Military Hospital AbbottabadCompleted
-
Giselle ShollerBeat NB Cancer Foundation; Because of Ezra; K C Pharmaceuticals Inc.Active, not recruitingNeuroblastoma RecurrentUnited States
-
Oulu University HospitalUnknownSinusitis | Acute Respiratory InfectionFinland
-
Cliniques universitaires Saint-Luc- Université...UnknownBisphosphonate-Associated Osteonecrosis of the JawBelgium